About
Aris Baras serves as Vice President and Head of the Regeneron Genetics Center (RGC), one of the largest human genetics programs in the world, spanning large-scale sequencing, informatics, and translational sciences using human genetics to advance and guide the development of Regeneron’s pipeline of important new medicines. He has established and leads several foundational genomics collaborations, such as with the Geisinger Health System to sequence at least 250,000 participants and with the UK Biobank to sequence 500,000 participants. The RGC has produced many high impact discoveries identifying new drug targets, validating existing development programs, and contributing important new gene discoveries. The RGC has sequenced more than 250,000 individuals to date, collaborating with more than 50 institutions around the world. Previously, Aris Baras held roles and responsibilities at Regeneron across R&D and business development. Prior to Regeneron, Aris Baras contributed to other biotech
Position in the VCSift Database
- • 5 investors at Regeneron are tracked.
- • 1 investors hold the Senior Vice President, Regeneron Pharmaceuticals, General Manager, Regeneron Genetics Center role in VCSift. Aris Baras is one of them.
- • 10,621 investors are based in New York, New York, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- New York, US
Contact Information
Find more investors like Aris
Search Investors